I believe that Fisher is a bit conflicted. They develop and market MDx equipment and consumables yet they also run a major online catalog exchange that features the equipment of competitors.
I used to use the Fisher relative popularity feature to track Biocartis' sales of Idylla systems. However, BCART launched their own sales force in the US so Fisher is no longer the only sales outlet.
In any event liquid biopsy is becoming more crowded that than many investors in the field realize.